United Therapeutics (BSP:U2TH34) Cyclically Adjusted Revenue per Share: R$13.16 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BSP:U2TH34 United Therapeutics Corp BSP:U2TH34
65 GF Score
Price R$133.00
GF Value R$96.04
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is United Therapeutics Cyclically Adjusted Revenue per Share?

United Therapeutics BSP:U2TH34 65 Cyclically Adjusted Revenue per Share is R$13.16 as of Mar. 2026. GuruFocus rates BSP:U2TH34 with a GF Score™ of 65/100 and a GF Value™ of R$96.04 (Significantly Overvalued). The stock has 7 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

United Therapeutics's adjusted revenue per share for the three months ended in Mar. 2026 was R$4.329. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is R$13.16 for the trailing ten years ended in Mar. 2026.

During the past 12 months, United Therapeutics's average Cyclically Adjusted Revenue Growth Rate was 8.80% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 8.80% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 10.20% per year. During the past 10 years, the average Cyclically Adjusted Revenue Growth Rate was 12.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of United Therapeutics was 35.70% per year. The lowest was 8.80% per year. And the median was 20.50% per year.

As of today (2026-07-18), United Therapeutics's current stock price is R$133.00. United Therapeutics's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 was R$13.16. United Therapeutics's Cyclically Adjusted PS Ratio of today is 10.11.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of United Therapeutics was 11.59. The lowest was 2.88. And the median was 5.90.


United Therapeutics  (BSP:U2TH34) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

United Therapeutics's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=133.00/13.16
=10.11

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of United Therapeutics was 11.59. The lowest was 2.88. And the median was 5.90.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


United Therapeutics Cyclically Adjusted Revenue per Share Related Terms


United Therapeutics Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for United Therapeutics's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

United Therapeutics Cyclically Adjusted Revenue per Share Chart

United Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 10.87 14.43 13.74

United Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 15.51 13.26 13.17 13.74 13.16

BSP:U2TH34 vs VTRS, NBIX, ZTS: Cyclically Adjusted Revenue per Share Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, United Therapeutics's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


United Therapeutics Cyclically Adjusted PS Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, United Therapeutics's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where United Therapeutics's Cyclically Adjusted PS Ratio falls into.


BSP:U2TH34
65GF Score
United Therapeutics Corp BSP:U2TH34
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

United Therapeutics Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, United Therapeutics's adjusted Revenue per Share data for the three months ended in Mar. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=4.329/330.2130*330.2130
=4.329

Current CPI (Mar. 2026) = 330.2130.

United Therapeutics Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201606 1.506 241.018 2.063
201609 1.437 241.428 1.965
201612 1.514 241.432 2.071
201703 1.262 243.801 1.709
201706 1.632 244.955 2.200
201709 1.582 246.819 2.117
201712 1.740 246.524 2.331
201803 1.454 249.554 1.924
201806 1.931 251.989 2.530
201809 1.927 252.439 2.521
201812 1.683 251.233 2.212
201903 1.593 254.202 2.069
201906 1.637 256.143 2.110
201909 1.880 256.759 2.418
201912 1.458 256.974 1.874
202003 1.974 258.115 2.525
202006 2.115 257.797 2.709
202009 2.301 260.280 2.919
202012 2.190 260.474 2.776
202103 2.302 264.877 2.870
202106 2.373 271.696 2.884
202109 2.466 274.310 2.969
202112 2.451 278.802 2.903
202203 2.409 287.504 2.767
202206 2.450 296.311 2.730
202209 2.778 296.808 3.091
202212 2.609 296.797 2.903
202303 2.662 301.836 2.912
202306 2.924 305.109 3.165
202309 3.028 307.789 3.249
202312 3.012 306.746 3.242
202403 3.395 312.332 3.589
202406 4.053 314.175 4.260
202409 4.284 315.301 4.487
202412 4.629 315.605 4.843
202503 4.706 319.799 4.859
202506 4.585 322.561 4.694
202509 4.532 324.800 4.608
202512 4.557 324.054 4.644
202603 4.329 330.213 4.329

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of R$13.16 mean?
United Therapeutics (BSP:U2TH34) has a Cyclically Adjusted Revenue per Share of R$13.16 as of Mar. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on United Therapeutics and its competitors.
Is United Therapeutics' Cyclically Adjusted Revenue per Share too high?
United Therapeutics' current Cyclically Adjusted Revenue per Share is R$13.16. Overall, United Therapeutics has a GF Score™ of 65/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does United Therapeutics' Cyclically Adjusted Revenue per Share compare to VTRS and NBIX?
United Therapeutics' Cyclically Adjusted Revenue per Share of R$13.16 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Drug Manufacturers company?
A good Cyclically Adjusted Revenue per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on United Therapeutics and its competitors. United Therapeutics's current Cyclically Adjusted Revenue per Share is R$13.16. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is United Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, United Therapeutics (BSP:U2TH34) is currently considered Significantly Overvalued. The stock's GF Value™ is R$96.04, compared to a current price of R$133.00 — trading 38.5% above its estimated fair value. The current Cyclically Adjusted Revenue per Share is R$13.16. United Therapeutics' overall GF Score™ is 65/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For United Therapeutics (BSP:U2TH34), the current Cyclically Adjusted Revenue per Share is R$13.16 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is United Therapeutics (BSP:U2TH34) Overvalued in 2026?

Based on GuruFocus' analysis, United Therapeutics stock appears to be overvalued. The current stock price of R$133.00 is trading 38.5% above its estimated GF Value™ of R$96.04. GuruFocus considers United Therapeutics to be Significantly Overvalued.

Key valuation signals for BSP:U2TH34:

  • Cyclically Adjusted Revenue per Share: R$13.16
  • GF Value™: R$96.04 vs. price of R$133.00 (38.5% above fair value)
  • GF Score™: 65/100 with 7 warning signs

No single metric tells the full story. See the BSP:U2TH34 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


United Therapeutics Business Description

Other Exchanges UTHR:USAUTH:Germany
Address 1000 Spring Street, Silver Spring, MD, USA, 20910
United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. It derives maximum revenue from the sale of Tyvaso DPI. Geographically, the company operates in United States and Rest of the World, of which United States generates majority of the revenue.
65GF Score

Get the complete analysis for BSP:U2TH34

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

R$133.00
Price
R$96.04
GF Value